Cytokines as Mediators of Lung Innate Immunity

  • T. J. Standiford
  • B. Merhad
  • W. C. Tsai
Part of the Update in Intensive Care Medicine book series (volume 31)

Abstract

The emergence of multi-drug resistant microbes in the immunocompromised host has made the treatment of bacterial, fungal, and mycobacterial infections of the lung increasingly difficult [1, 2, 3]. This rather ominous trend underscores the need to better understand the immune host response in order to develop immunotherapies directed at these responses. Effective host defense against common bacterial pathogens of the respiratory tract is primarily dependent upon the rapid clearance of the etiologic agent from the lung [4, 5]. Innate, or natural immunity, is the principal pathway for effective elimination of bacterial organisms that have reached the alveolus. The three principal phagocytic cells that constitute innateimmunity in the lung include resident alveolar macrophages, recruited neutrophils, and mononuclear phagocytes. In addition, these cells, as well as resident T cells (particularly γδ-T cells) and natural killer (NK) cells, participate in innate immune responses in the lung via the elaboration of important activating and/or chemotactic cytokines. In contrast to bacterial infection, host responses to intracellular bacteria, fungi, mycobacterium and viruses are more complex and require both the phagocytic system, as well as antibody-mediated and cell-mediated immunity [4, 5, 6, 7]. While neutrophils play a role in host defense against some of these pathogens, the recruitment and/or activation of macrophages and CD44+ T cells is essential for the effective clearance of many intracellular pathogens from the lung.

Keywords

Placebo Pneumonia Influenza Tuberculosis Interferon 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davies J (1994) Inactivation of antibiotics and dissemination of resistance genes. Science 264:375–382PubMedCrossRefGoogle Scholar
  2. 2.
    Wunderink R (1995) Ventilator-associated pneumonia. Clin Chest Med 16:173–193PubMedGoogle Scholar
  3. 3.
    Center for Disease Control (1997) Update: Staphylococcus aureus with reduced susceptibility to Vancomycin — United States. Morb Mortal Wkly Rep 46:813–815Google Scholar
  4. 4.
    Toews GB, Gross GN, Pierce AK (1979) The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 120:559–566PubMedGoogle Scholar
  5. 5.
    Nelson S, Mason CM, Kolls JK (1995) Pathophysiology of pneumonia. Clin Chest Med 16:1–12PubMedGoogle Scholar
  6. 6.
    Murphy J (1989) Cryptococcosis. In: Cox RA (ed) Immunology of the fungal diseases. CRC Press, Boca Raton, pp 93–138Google Scholar
  7. 7.
    DesPrez RM, Heim CR (1990) Mycobacterium tuberculosis. In: Mandell GL, Douglas RG, Bennett JE (eds) Principles and practice of infectious diseases, edn 3. Churchill Livingstone, New York, pp 1877–1905Google Scholar
  8. 8.
    Standiford TJ, Huffnagle GB (1997) Cytokines in host defense against pneumonia. J Invest Med 45:335–345Google Scholar
  9. 9.
    Kolls JK, Nelson S, Summer WR (1993) Recombinant cytokines and pulmonary host defense. Am J Med Sci 306:330–335PubMedCrossRefGoogle Scholar
  10. 10.
    Laichalk LL, Kunkel SL, Stricter RM, Danforth JM, Baile M, Standiford TJ (1996) Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 64:5211–5218PubMedGoogle Scholar
  11. 11.
    Huffnagle GB, Toews GB, Burdick MD, et al (1996) Afferent phase production of TNF-α is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 157:4529–4536PubMedGoogle Scholar
  12. 12.
    Tracey KJ, Beutler B, Lowry SF, Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470–474PubMedCrossRefGoogle Scholar
  13. 13.
    Le J, Vilcek J (1987) Tumor necrosis factor and interleukin-1: Cytokines with multiple overlapping biological activities. Lab Invest 56:234–248PubMedGoogle Scholar
  14. 14.
    Oswald IP, Wynn TA, Sher A, James SL (1992) Interleukin 10 inhibits macrophage microbicidal activity by blocking endogenous production of tumor necrosis factor a required as a costimulatory factor for interferon-ψ-induced activation. Proc Natl Acad Sci USA 89: 8676–8680PubMedCrossRefGoogle Scholar
  15. 15.
    Tan AM, Ferrante A, Goh DH, Robertson DM, Gripps AW (1995) Activation of the neutrophil bactericidal activity for non typeable Haemophilus influenza by tumor necrosis factor and lymphotoxin. Pediatr Res 37:155–159PubMedCrossRefGoogle Scholar
  16. 16.
    Dehoux MS, Boutten A, Ostinelli J, et al (1994) Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Grit Care Med 150:710–716Google Scholar
  17. 17.
    Gosselin D, DeSanctis J, Boule M, Skamene E, Matouk C, Radzioch D (1995) Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 63:3272–3278PubMedGoogle Scholar
  18. 18.
    Brieland J, Remick D, Freeman P, Hurley M, Fantone J, Engleberg N (1995) In vivo regulation of replicative Legionella pneumophila lung infection by endogenous tumor necrosis factor alpha and nitric oxide. Infect Immun 63:3253–3258PubMedGoogle Scholar
  19. 19.
    Takashima K, Tateda K, Matsumoto T, Lizawa Y, Nakao M, Yamaguchi K (1997) Role of tumor necrosis factor alpha in pathogenesis of pneumococcal pneumonia in mice. Infect Immun 65:257–260PubMedGoogle Scholar
  20. 20.
    Kolls JK, Lei D, Nelson S, Summer WR, Greenberg S, Beutler B (1995) Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 171:570–575PubMedCrossRefGoogle Scholar
  21. 21.
    Baggiolini M, Dewald B, Moser B (1997) Human chemokines: an update. Annu Rev Immunol 15:675–705PubMedCrossRefGoogle Scholar
  22. 22.
    Huffnagle GB, Stricter RM, Kunkel S L, Toews GB, Standiford TJ (1996) The role of chemokines in pneumonia. In: Koch A, Stricter R (eds) Chemokines in disease. R. G. Landis Co, Texas, pp 151–168Google Scholar
  23. 23.
    Greenberger MJ, Stricter RM, Kunkel SL, et al (1996) Neutrahzation of MIP-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pneumonia. J Infect Dis 173:159–165PubMedCrossRefGoogle Scholar
  24. 24.
    Tsai WC, Stricter RM, Wilkowski JM, et al (1998) Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice. J Immunol 161:2435–2440PubMedGoogle Scholar
  25. 25.
    Murphy PM (1997) Neutrophil receptors for interleukin-8 and CXC chemokines. Semin Hematol 34:311–318PubMedGoogle Scholar
  26. 26.
    Jenson W, Rose R, Wasserman A, Kalb T, Anton K, Remold H (1987) In vitro activation of the antibacterial activity of human pulmonary macrophages by recombinant gamma interferon. J Infect Dis 155:574–577CrossRefGoogle Scholar
  27. 27.
    Beck J, Liggitt H, Brunette E, Fuchs H, Shellito J, Debs R (1991) Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gammma interferon. Infect Immun 59:3859–3862PubMedGoogle Scholar
  28. 28.
    Skerrett S, Martin T (1994) Intratracheal interferon-y augments pulmonary defenses in experimental legionellosis. Am J Respir Grit Care Med 149:50–58Google Scholar
  29. 29.
    Rubins JB, Pomeroy C (1997) Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect Immun 65:2975–2977PubMedGoogle Scholar
  30. 30.
    Kolls JK, Lei D, Nelson S, Summer WR, Shellito JE (1997) Pulmonary cytokine gene therapy. Adenoviral-mediated murine interferon gene transfer compartmentally activates alveolar macrophages and enhances bacterial clearance. Chest 111 (suppl 6): 104SPubMedCrossRefGoogle Scholar
  31. 31.
    Chehimi J, Trinchieri G (1994) Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Chn Immunol 14:149–159CrossRefGoogle Scholar
  32. 32.
    Kawakami K, Tohyama M, Xie Q, Saito A (1996) IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 104: 208–214PubMedCrossRefGoogle Scholar
  33. 33.
    Greenberger MJ, Kunkel SL, Stricter RM, et al (1996) IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 157:3006–3012PubMedGoogle Scholar
  34. 34.
    Howard M, O’Garra A, Ishida H, Malefyt RD, De Vries J (1992) Biological properties of interleukin 10. J Clin Immunol 12:239–247PubMedCrossRefGoogle Scholar
  35. 35.
    Laichalk LL, Danforth JM, Standiford TJ (1996) Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity. FEMS Immunol Med Microbiol 15:181–187PubMedCrossRefGoogle Scholar
  36. 36.
    Rolph P, Nakoinz I, Sampson-Johannes A, et al (1992) IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 148:808–814Google Scholar
  37. 37.
    Kasama T, Stricter RM, Lukacs NW, Burdick MD, Kunkel SL (1994) Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 152:3559–3569PubMedGoogle Scholar
  38. 38.
    Howard M, Muchamucl T, Andrade S, Menon S (1993) Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177:1205–1208PubMedCrossRefGoogle Scholar
  39. 39.
    Standiford TJ, Stricter RM, Lukacs NW, Kunkel SL (1995) Neutrahzation of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 155:2222–2229PubMedGoogle Scholar
  40. 40.
    Greenberger MJ, Stricter RM, Kunkel SL, Danforth J, Goodman R, Standiford TJ (1995) Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 155:722–729PubMedGoogle Scholar
  41. 41.
    van der Poll T, Marchant A, Keogh C, Goldman M, Lowry S (1996) Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 174:994–1000PubMedCrossRefGoogle Scholar
  42. 42.
    Volk HD, Reinke P, Krausch D, et al (1996) Monocyte deactivation — rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22 (suppl 4): S474–S481PubMedCrossRefGoogle Scholar
  43. 43.
    Docke WD, Randow F, Syrbe U, et al (1997) Monocyte deactivation in septic patients: Restoration by IFN-y treatment. Nat Med 3:678–681PubMedCrossRefGoogle Scholar
  44. 44.
    Munoz CJ, Carlet C, Fitting C, Misset B, Bleroit JP, Cavaillon JM (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Chn Invest 88:1747–1754CrossRefGoogle Scholar
  45. 45.
    Wakefield CH, Gary PD, Foulds S J, Monson RT, Guillou PJ (1993) Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 80:205–209PubMedCrossRefGoogle Scholar
  46. 46.
    Christou NV (1985) Host-defense mechanisms in surgical patients: a correlative study of the delayed hypersensitivity skin-test response, granulocyte function and sepsis. Can J Surg 28:39–49PubMedGoogle Scholar
  47. 47.
    Brun-Buisson C, Doyon F, Carlet J, et al (1995) Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. JAMA 274:968–973PubMedCrossRefGoogle Scholar
  48. 48.
    Randow F, Syrbe U, Meisel C, et al (1995) Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor β. J Exp Med 181:1887–1892PubMedCrossRefGoogle Scholar
  49. 49.
    Walley KR, Lukacs NW, Standiford TJ, Stricter RM, Kunkel SL (1996) Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64:4733–4738PubMedGoogle Scholar
  50. 50.
    Steinhauser ML, Hogaboam CM, Kunkel SL, Lukacs NW, Stricter RM, Standiford TJ (1999) IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 161:2435–2440Google Scholar
  51. 51.
    Sawa T, Corry DB, Cropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP (1997) IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 159: 2858–2866PubMedGoogle Scholar
  52. 52.
    Cohen J (1995) IL-12 deaths: Explanation and a puzzle. Science 270:908PubMedCrossRefGoogle Scholar
  53. 53.
    Laichalk LL, Bucknell KA, Huffnagle GB, et al (1998) Intrapulmonary delivery of tumor necrosis factor agonist peptide augments host defense in murine gram-negative bacterial pneumonia. Infect Immun 66:2822–2826PubMedGoogle Scholar
  54. 54.
    Wilson JM (1995)Molecular medicine. Adenoviruses as gene-delivery vehicles. N Engl J Med 334:1185–1187CrossRefGoogle Scholar
  55. 55.
    Standiford TJ, Wilkowski JM, Sisson TH, et al (1999) Intrapulmonary tumor necrosis factor gene therapy increases bacterial clearance and survival in murine gram-negative pneumonia. Hum Gene Ther 10:899–909PubMedCrossRefGoogle Scholar
  56. 56.
    Bramson J, Hitt M, Gallichan WS, Rosenthal K, Gauldie J, Graham EL (1995)Construction and characterization of an adenovirus expressing IL-12. Hum Gene Ther 7:333–340CrossRefGoogle Scholar
  57. 57.
    Preheim LC, Snitily MU, Gentry MJ (1996) Effects of granulocyte colony-stimulating factor in cirrhotic rats with pneumococcal pneumonia. J Infect Dis 174:225–228PubMedCrossRefGoogle Scholar
  58. 58.
    Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE (1995) Granulocyte colonystimulating factor versus placebo in addition to penicillin G in randomized blinded study of gram-negative pneumonia sepsis: Analysis of survival and multisystem organ failure. Blood 86:1301–1309PubMedGoogle Scholar
  59. 59.
    van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF (1997) Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 176:439–444PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • T. J. Standiford
    • 1
  • B. Merhad
    • 1
  • W. C. Tsai
    • 2
  1. 1.Department of Internal Medicine Pulmonary Inpatient ServiceUniversity of Michigan Medical CenterAnn ArborUSA
  2. 2.Department of Pediatric PulmonologyUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations